medRxiv PreprintsInternational20 November 2026
LCatlas: A Point-Of-Care Tool for Predicting Immunotherapy Outcomes in Non-Small Cell Lung Cancer
This is an official announcement record
Firsthand records what medRxiv Preprints announced and links to the original. The wording below is theirs, not ours.
Non-small cell lung cancer (NSCLC) remains a leading cause of cancer mortality, with a minority of patients experiencing durable responses to first-line immune checkpoint inhibitors (ICIs). Currently, there are no easily accessible tools to predict clinical benefit to first-line immunotherapy. To address this gap, we developed LCatlas (https://www.lcatlas.org), a point-of-care web application designed to predict immunotherapy outcomes and inform evidence-based treatment decisions. Using data from 79 NSCLC patients receiving first-line immunotherapy, we extracted demographic, clinical, and mole
Read the official announcement
Opens www.medrxiv.org
More from medRxiv Preprints
- Unmet needs of Polish patients with cystic fibrosis seen through the lens of crowdfunding20 November 2026
- Motherly Plus: Study Protocol of a Randomized Controlled Trial Evaluating a Smartphone-Assisted Single-Session Psychotherapy Intervention for Postpartum Depression20 November 2026
- Targeting memory consolidation in major depression via pharmacological slow-wave sleep promotion20 November 2026
- Epidemiology of Cardiac Structure and Function Among African Caribbeans in Tobago: A Population-based Cohort Study20 November 2026
- Depressive Symptom Trajectories and Incident Cognitive Impairment by Outcome Ascertainment20 November 2026
This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.